Table 1.
Sample characteristics (n = 99)
| Ketamine 0.1 mg/kg n=18 | Ketamine 0.2 mg/kg n=20 | Ketamine 0.5 mg/kg n=22 | Ketamine 1.0 mg/kg n=20 | Midazolam 0.045 mg/kg n=19 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| M/% | SD | M/% | SD | M/% | SD | M/% | SD | M/% | SD | |
| Demographics and pharmacologically relevant variables | ||||||||||
| Age | 43.1 | 11.9 | 45.5 | 14.6 | 48.6 | 12.9 | 47.4 | 10.1 | 45.6 | 13.8 |
| BMI | 25.2 | 3.1 | 24.9 | 3.7 | 25.3 | 5.7 | 26.1 | 3.8 | 26.3 | 4.1 |
| Gender (% fem.) | 55.6 | 45.0 | 50.0 | 40.0 | 57.9 | |||||
| Hispanic (% yes) | 5.6 | 0.0 | 9.1 | 0.0 | 0.0 | |||||
| Race | ||||||||||
| White | 66.7 | 100.0 | 90.9 | 90.0 | 94.7 | |||||
| Asian | 16.7 | 0.0 | 4.6 | 5.0 | 0.0 | |||||
| Black | 16.7 | 0.0 | 0.0 | 5.0 | 0.0 | |||||
| Other | 0.0 | 0.0 | 4.6 | 0.0 | 5.3 | |||||
| Concomitant medications (% used) | ||||||||||
| Benzodiazepines | 50.0 | 50.0 | 45.5 | 45.0 | 31.6 | |||||
| Non-benzodiazepine hypnotics | 27.8 | 25.0 | 9.1 | 25.0 | 21.1 | |||||
| SSRIs | 44.4 | 60.0 | 54.6 | 50.0 | 52.6 | |||||
| SNRIs | 27.8 | 35.0 | 31.8 | 20.0 | 26.3 | |||||
| TCAs | 5.6 | 0.0 | 4.6 | 5.0 | 0.0 | |||||
| Other antidepressant(s) | 44.4 | 55.0 | 59.1 | 40.0 | 57.9 | |||||
| Clinical severity at baseline | ||||||||||
| No. of failed antidepressants for current episode | 3.3 | 1.3 | 3.7 | 1.6 | 2.7 | 1.2 | 2.9 | 1.2 | 2.9 | 1.4 |
| HAM-D-6 | 12.6 | 1.8 | 12.8 | 2.5 | 12.6 | 1.5 | 12.6 | 2.1 | 13.1 | 2.3 |
| MADRS | 33.8 | 5.9 | 34.5 | 8.5 | 31.6 | 3.9 | 32.7 | 5.9 | 33.6 | 7.1 |
| CGI-S | 5.0 | 0.8 | 5.2 | 0.7 | 4.9 | 0.6 | 5.2 | 0.8 | 5.0 | 0.7 |
| CGI-I | 3.9 | 0.3 | 4.1 | 0.2 | 4.1 | 0.7 | 4.0 | 0.5 | 4.2 | 0.6 |
| SDQ | 3.5 | 0.5 | 3.5 | 0.5 | 3.5 | 0.6 | 3.4 | 0.4 | 3.4 | 0.5 |
| PAS | 19.3 | 12.2 | 20.5 | 15.4 | 20.6 | 11.7 | 21.3 | 14.7 | 21.3 | 12.1 |
Benzodiazepines included Alprazolam, Clonazepam, Clorazepic acid, Diazepam, and Lorazepam; non-benzodiazepine hypnotics included Zaleplon, Zolpidem, and Trazodone
BMI body mass index, SSRIs selective serotonin reuptake inhibitors (incl. Fluoxetine, Citalopram, Escitalopram, Paroxetine, Sertraline, and Vilazodone), SNRIs serotonin–norepinephrine reuptake inhibitors (incl. Desvenlafaxine, Duloxetine, Venlafaxine, and Venlafaxine hydrochloride), TCAs tricyclic antidepressants (incl. Clomipramine and Nortriptyline), other antidepressants included Bupropion, Mirtazapine, Vortioxetine, HAM-D-6 Hamilton Rating Scale for Depression, 6-item version, MADRS Montgomery–Asberg Depression Rating Scale, CGI-S and CGI Clinical Global Impression of Severity and Improvement scales, SDQ Symptoms of Depression Questionnaire, PAS Positive Affect Scale